Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and CD&R sign Opella share purchase agreement
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Execution of a share buyback agreement for up to €2 billion
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces buy back of shares from L’Oréal
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Opella reaches study milestone for Cialis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q4 2024 Aide-mémoire
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi in discussions to sell a controlling stake in Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS